NYSCF Global Stem Cell Array®
Developed by NYSCF scientists and engineers, the NYSCF Global Stem Cell Array® enables research to functionalize human genetics, merging data from the human genome with our own biology to accelerate discovery of new therapies.
This pioneering automation technology allows NYSCF to:
- Standardize and scale out production of induced pluripotent stem (iPS) cells, which are stem cells made from an individual’s own skin or blood cells.
- Study iPS cells from thousands of patients, reflecting the genetic diversity of the global population and enabling scientists to detect patterns that are only discernible when examining a large population of patients, and which show how different genetic mutations impact individual disease symptoms.
- Conduct “clinical trials in a dish” using the actual affected human cell types affected by disease and from patients, testing drugs and therapies directly on human cells for precision drug development.
- Develop more effective, safer, and less expensive new drugs to target the causes of disease, by factoring in genetic differences during the development process. This revolutionary approach will help “de-risk” projects that pharmaceutical companies would typically avoid.
In 2015, NYSCF scientists published a paper describing the NYSCF Global Stem Cell Array® in the journal Nature Methods. Read the publication and learn more about the NYSCF Array’s capabilities and the validation of NYSCF-generated stem cell lines in the press release. If you are interested in collaborative opportunities using the NYSCF Global Stem Cell Array®, please contact email@example.com.